LDL cholesterol is the lipid number most adults know. It shows up on every standard panel, it has been the target of guideline-driven treatment for thirty years, and it is what your physician will likely mention first. It is also a derived estimate, not a direct measurement, and in a meaningful fraction of patients it understates cardiovascular risk. Apolipoprotein B, by contrast, is a direct count of the atherogenic particles actually circulating in your blood. The evidence that ApoB is a stronger predictor of cardiovascular events has accumulated for fifteen years, and the major guideline bodies have begun to reflect this. This article walks through the biology, the comparative evidence, when the two numbers disagree, and what the 2026 guideline picture looks like.
What each number actually measures
LDL-C is the concentration of cholesterol carried in low-density lipoprotein particles, reported in milligrams per deciliter or millimoles per liter. In most clinical labs it is calculated using the Friedewald equation: LDL-C = total cholesterol − HDL-C − (triglycerides ÷ 5). The Friedewald estimate becomes unreliable when triglycerides exceed about 400 mg/dL, and labs increasingly use the Martin-Hopkins formula or direct LDL-C measurement instead. Even the direct measurement is a quantification of cholesterol mass per volume, not of particles.
ApoB is the structural protein that wraps every atherogenic lipoprotein particle: LDL, VLDL, IDL, and Lp(a). There is exactly one ApoB molecule per particle. Measuring ApoB therefore counts the number of atherogenic particles circulating, expressed in mg/dL. The assay is standardized, widely available, and reasonably inexpensive (often under $30 at commercial labs in the United States).
The conceptual difference matters because atherosclerosis is driven by particles crossing the endothelium and depositing in the arterial wall, not by the mass of cholesterol those particles happen to be carrying. A small dense LDL particle deposits the same way as a large fluffy LDL particle. The lesion-forming event is particle-driven. The marker that counts particles is closer to the mechanism than the marker that estimates cargo.
The evidence ApoB is a stronger predictor
Sniderman et al. (JAMA Cardiology, 2019) performed the most comprehensive meta-analysis comparing the three commonly reported atherogenic markers: ApoB, non-HDL cholesterol, and LDL-C. Across 12 prospective epidemiological studies including more than 230,000 participants, ApoB had the strongest association with risk of myocardial infarction, with a relative risk ratio that outperformed both non-HDL-C and LDL-C. The relative risk per standard deviation of ApoB was approximately 1.43, compared to roughly 1.25 for LDL-C and 1.34 for non-HDL-C.
Marston et al. (NEJM, 2022) extended this in a large pooled analysis of statin trial participants (n=389,529). Within trial cohorts where LDL-C was being actively lowered, residual cardiovascular risk tracked with ApoB more closely than with LDL-C. In particular, among patients whose LDL-C was reduced to guideline target but whose ApoB remained elevated, event rates were higher than in patients with both markers reduced. The reverse pattern (LDL-C above target, ApoB at target) did not show elevated risk to the same degree.
The mechanistic interpretation: LDL-C tracks risk well when LDL particles carry an average amount of cholesterol per particle. When particles are smaller and more numerous (a common pattern in metabolic syndrome, insulin resistance, and type 2 diabetes), the same LDL-C corresponds to a much larger particle count, and LDL-C underestimates risk. ApoB, because it counts particles directly, does not have this blind spot.
The European Atherosclerosis Society consensus statement (Ference et al., European Heart Journal, 2017) was already explicit a decade ago: cumulative exposure to ApoB-containing lipoproteins is the most consistent predictor of atherosclerotic cardiovascular disease in epidemiological, Mendelian randomization, and randomized trial data combined.
When the two numbers disagree (discordance)
The clinically interesting case is the patient whose LDL-C and ApoB disagree, called discordance. Cromwell et al. (Journal of Clinical Lipidology, 2007) characterized the prevalence: in a cohort of more than 3,000 adults in the Framingham Offspring Study, roughly 30 percent showed meaningful discordance between LDL-C and apoB or LDL particle number.
The most common discordant pattern: LDL-C in the "normal" range (under 130 mg/dL) with ApoB elevated (over 90 mg/dL). This pattern is characteristic of small dense LDL phenotype, frequently seen with elevated triglycerides, low HDL-C, abdominal adiposity, insulin resistance, or polycystic ovary syndrome. A patient with this profile may be told their "cholesterol is fine" based on LDL-C while carrying a 30 to 50 percent higher cardiovascular event risk than the LDL-C number would suggest.
The reverse pattern (LDL-C elevated, ApoB normal) is less common and typically reflects large buoyant LDL particles. It is associated with somewhat lower atherogenic risk per unit of LDL-C than the average case, although risk is still elevated relative to a person with both markers low.
Cole et al. (Journal of the American College of Cardiology, 2013) showed that in discordant patients, ApoB was a substantially better predictor of incident cardiovascular events than LDL-C. Among patients with low LDL-C but high ApoB, event rates were comparable to patients with high LDL-C, contradicting what a clinician relying on LDL-C alone would conclude.
The practical implication: if you are running cardiovascular risk decisions on LDL-C alone, you are accepting a roughly one-in-three chance that the number you are using does not reflect your actual particle burden.
How ApoB is interpreted
The Sniderman et al. (Lancet Diabetes and Endocrinology, 2019) Toronto-led consensus paper gives the most widely cited thresholds. Approximate decision points for adults at moderate cardiovascular risk:
- Under 65 mg/dL: low risk profile, often the target for secondary prevention after a cardiovascular event.
- 65 to 80 mg/dL: low-to-moderate, generally considered acceptable in primary prevention without other major risk factors.
- 80 to 100 mg/dL: moderate, particularly important to address if other risk factors are present.
- Over 100 mg/dL: elevated, warrants attention.
- Over 130 mg/dL: high.
These are population thresholds. The Peter Attia practice and several other longevity-oriented clinicians argue for lower personal targets in patients with strong family history of premature atherosclerosis or with high coronary calcium scores. The general principle is that ApoB is dose-dependent: lower exposure over more years equals less accumulated arterial damage, and the relationship appears to be linear without a threshold.
What the 2026 guideline picture looks like
The 2024 European Society of Cardiology lipid guideline update gave ApoB a Class I recommendation as an alternative risk marker, particularly in patients with elevated triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C. The 2018 ACC/AHA cholesterol guideline mentioned ApoB only as a "risk-enhancing factor." The 2024 ACC/AHA scientific statement (Grundy et al.) gave ApoB substantially more weight, and the expected 2026 update is anticipated to formalize ApoB as a preferred secondary marker alongside LDL-C, particularly in discordant patients.
The cost equation has also shifted. ApoB testing was historically several times the price of a standard lipid panel. By 2025 most US commercial labs price ApoB under $30 and most direct-to-consumer longevity panels include it as standard. There is no longer a cost barrier to ordering it.
What changes ApoB
The interventions that move LDL-C also move ApoB, with magnitude that depends on the mechanism.
Statins lower both LDL-C and ApoB, with ApoB typically dropping a slightly smaller percentage than LDL-C because statins shift particle composition toward fewer, more cholesterol-loaded LDL particles in some patients.
PCSK9 inhibitors lower both markers substantially and in similar proportions.
Bempedoic acid lowers LDL-C by roughly 17 percent and ApoB by roughly 13 percent in monotherapy.
Dietary saturated fat reduction typically lowers both markers by 5 to 15 percent, with most of the change visible at 4 to 6 weeks.
Soluble fiber (oats, psyllium, beta-glucan) at 5 to 10 grams per day produces modest reductions of 5 to 8 percent in LDL-C and similar in ApoB.
Endurance training produces small ApoB reductions independent of weight loss, larger reductions when combined with body fat reduction.
The metric that does not respond predictably: high intensity interval training without dietary change produces inconsistent LDL-C and ApoB effects across studies.
Key takeaways
- LDL-C is a derived estimate of cholesterol mass. ApoB is a direct count of atherogenic particles. The mechanism of atherosclerosis is particle-driven, not cargo-driven.
- ApoB outperforms LDL-C and non-HDL-C as a predictor of myocardial infarction in meta-analyses of more than 230,000 participants.
- Roughly one in three adults shows discordance between LDL-C and ApoB. The most common pattern (low LDL-C, high ApoB) is dangerous because it falsely reassures.
- ApoB under 80 mg/dL is typically targeted for primary prevention. Lower targets apply if family history or coronary calcium argue for more aggressive intervention.
- ApoB testing now costs under $30 in most US commercial labs. There is no longer a cost case for skipping it.
Sources
1. Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology. 2019;4(12):1287-1295. 2. Marston NA, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes. NEJM. 2022;386:1923-1934. 3. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. European Heart Journal. 2017;38(32):2459-2472. 4. Cromwell WC, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study. Journal of Clinical Lipidology. 2007;1(6):583-592. 5. Cole TG, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies. Journal of the American College of Cardiology. 2013;61(20):2076-2089. 6. Sniderman AD, et al. Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol. Current Opinion in Lipidology. 2014;25(6):461-467. 7. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. 8. Grundy SM, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139:e1082-e1143.
---
Want VITA to do this for you automatically? Join the waitlist